References
- Bartlett NL, Sharman JP, Oki Y, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas. Blood 2013;122(Suppl. 1): Abstract 848.
- Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123:3095–3100.
- Krathen M, Sundram U, Bashey S, et al. Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression. Blood 2012;120(Suppl. 1): Abstract 797.
- Hill BT, Tubbs RR, Smith MR. Complete remission of CD30 positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin. Leuk Lymphoma 2014;55: XXX–XXX.
- Tan TH, Grove, LE, Lynch, CM. Effect of renal impairment on the pharmacokinetics of brentuximab vedotin, an antibody-drug conjugate, in patinets with CD30-positive hematologic malignancies. Clin Pharmacol Ther 2013;93:S17.
- Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.